Sugi Predict

Sugi Predict / Compounds / SCHEMBL2209204

SCHEMBL2209204

SCHEMBL2209204

CNC(C)C(=O)Nc1ncc(-c2ccc(F)cc2)n(CC(=O)N2Cc3ccccc3C2)c1=O

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.39
▸ MAPT P10636 1/20 0.39
▸ XIAP P98170 7/20 0.37
▸ NAMPT P43490 2/20 0.36
▸ MAPK1 P28482 2/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ ELANE P08246 1/20 0.35
▸ GLA P06280 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ SAE1 Q9UBE0 1/20 0.34
▸ UBA2 Q9UBT2 1/20 0.34
▸ GRIN2B Q13224 2/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2209196 1.00 LMNA (0.39) LMNAMAPTXIAPNAMPTMAPK1
SCHEMBL2211700 0.84 ELANE (0.47) ELANE
SCHEMBL2212238 0.84 MAPT (0.37) LMNAMAPTXIAPSMN1; SMN2ELANE
SCHEMBL2212228 0.84 MAPT (0.37) LMNAMAPTXIAPSMN1; SMN2ELANE
SCHEMBL2209206 0.84 ELANE (0.47) ELANE
SCHEMBL2209197 0.80 XIAP (0.38) LMNAMAPTXIAPMAPK1NPC1
SCHEMBL2209205 0.80 XIAP (0.38) LMNAMAPTXIAPMAPK1NPC1
SCHEMBL3831619 0.80 ELANE (0.32) LMNAMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2211912 0.79 ELANE (0.43) ELANE
SCHEMBL2209970 0.79 F7 (0.49) MAPTNPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048886-B2 Substituted pyrazine-3-one-derivatives as IAP inhibitors NOVARTIS AG (CH) 2011-11-01 — — US claimed
EP-2099769-B1 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2011-07-27 — — EP claimed
US-20100249405-A1 Organic Compounds NOVARTIS AG 2010-09-30 — — US claimed
CN-101535273-A 6-oxo.-1, 6-dihydropyrimidin-2-yls in the treatment of proliferative diseases NOVARTIS AG (CH) 2009-09-16 — — CN claimed
US-20110319614-A1 Organic Compounds NOVARTIS AG (CH) 2011-12-29 — — US disclosed
US-8048886-B2 Substituted pyrazine-3-one-derivatives as IAP inhibitors NOVARTIS AG (CH) 2011-11-01 — — US disclosed
EP-2099769-B1 6-OXO.-1, 6-DIHYDROPYRIMIDIN-2-YLS IN THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2011-07-27 — — EP disclosed
US-20100249405-A1 Organic Compounds NOVARTIS AG 2010-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319614-A1 Organic Compounds XIAP, BIRC5, BIRC3 LMNA 1667/4885MAPT 520/4885XIAP 1/4885
US-20100249405-A1 Organic Compounds XIAP, BIRC5, BIRC3 LMNA 1667/4885MAPT 520/4885XIAP 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.